NCT00405340View on ClinicalTrials.gov

Rituximab in the Treatment of Idiopathic Membranous Nephropathy

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

July 31, 2010

Study Completion Date

April 30, 2012

Conditions

Membranous Nephropathy

Interventions

DRUG

Rituximab

Patients will received rituximab 4 weekly doses of rituximab 375 mg/m2 at baseline. Patients will be retreated at 6 months.

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Mayo Clinic

OTHER

NCT00405340 - Rituximab in the Treatment of Idiopathic Membranous Nephropathy | Biotech Hunter | Biotech Hunter